Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.61 |
| ▸ | CA2 | P00918 | 5/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.61 |
| ▸ | CA7 | P43166 | 4/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | APOB | P04114 | 1/20 | 0.43 |
| ▸ | MTTP | P55157 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590871 | 0.85 | CA1 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6199303 | 0.84 | APOB (0.45) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6196616 | 0.84 | APOB (0.45) | CA1CA2CA12CA7CA14 | |
| SCHEMBL9505624 | 0.81 | CA1 (0.63) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1545211 | 0.80 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1545000 | 0.80 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL29878515 | 0.80 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1545004 | 0.80 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6583483 | 0.80 | CA1 (0.64) | CA1CA2CA12CA7CA14 | |
| SCHEMBL8008813 | 0.80 | CA1 (0.64) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4642455-A1 | METHOD OF TREATING TAUOPATHIES | GT Gain Therapeutics SA (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024141998-A1 | METHOD OF TREATING TAUOPATHIES | GT GAIN THERAPEUTICS SA (CH) | 2024-07-04 | — | — | WO | disclosed |
| WO-2008113795-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113795-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| US-4192888-A | Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | CA1 3591/4885CA2 752/4885CA12 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.